Effects of radiation therapy on brain function in glioma patients
Neuropsychological and Oncological Outcomes in Grade 2 or 3 Glioma Patients Undergoing Postoperative Modern Radiotherapy - A Prospective Follow-up Study
This study is testing how radiation therapy affects brain function and survival in patients with low-grade gliomas after their surgery.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 20 Years to 84 Years |
| Sex | All |
| Sponsor | Chang Gung Memorial Hospital Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Taoyuan) |
| Trial ID | NCT03534050 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the neuropsychological and oncological outcomes in patients with grade 2 or 3 gliomas who undergo postoperative modern radiotherapy. The study aims to assess the impact of radiation therapy on neurocognitive functions and overall survival rates following surgical intervention. Patients eligible for the trial include those who have undergone craniotomy or biopsy for low-grade gliomas and are recommended for adjuvant radiation therapy due to specific high-risk features. The trial will monitor cognitive function over time to understand the potential side effects of treatment.
Who should consider this trial
Good fit: Ideal candidates are adults with infiltrative low-grade gliomas who have undergone surgery and are recommended for postoperative radiation therapy.
Not a fit: Patients with high-grade gliomas or those who have previously received cranial irradiation will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve treatment protocols for glioma patients by balancing effective tumor control with the preservation of cognitive function.
How similar studies have performed: Previous studies have shown varying degrees of success in managing low-grade gliomas with radiation therapy, but this specific approach to assessing neurocognitive outcomes is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients with infiltrative low-grade gliomas who have received craniotomy plus tumor removal or at least biopsy with pathologic conformation; brain radiation therapy is recommended owning to some high-risk features including subtotal resection (STR) or age at craniotomy older than 40 years old * Good performance status no worse than Eastern Cooperative Group (ECOG) of 2 or a general status of Karnofsky Score (KPS) at least 70 % Exclusion Criteria: * A pathological diagnosis confirmed to be WHO grade IV glioma (i.e., glioblastoma multiforme) or grade I disease (i.e., pilocystic astrocytoma) * Radiographic evidence of gliomatosis cerebri * Prior cranial irradiation for any reasons
Where this trial is running
Taoyuan
- Chang Gung Memorial Hospital — Taoyuan, Taiwan (Recruiting)
Study contacts
- Study coordinator: Shinn-Yn Lin, M.D.
- Email: rt3126@gmail.com
- Phone: +886-33281200
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.